Navigation Links
Dendreon Reports First Quarter 2009 Financial Results
Date:5/6/2009

SEATTLE, May 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2009. Revenue for the first quarter of 2009 was $30,000 compared to $31,000 for the quarter ended March 31, 2008.

Dendreon's total operating expenses for the three months ended March 31, 2009 were $17.0 million compared to $19.2 million for the same period in 2008. The net loss for the quarter ended March 31, 2009 was $15.4 million, or $0.16 per share compared to a net loss for the same quarter of 2008 of $19.5 million, or $0.23 per share. Cash, cash equivalents, short-term, and long-term investments at March 31, 2009 totaled $91.2 million compared to $108.5 million at December 31, 2008.

Recent Events:

  • Reported final analysis of the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) Phase 3 trial for PROVENGE (sipuleucel-T) which demonstrated a statistically significant increase in overall survival. Data were presented at the American Urological Association (AUA) Annual Meeting. Based on these data, the Company intends to amend its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in the fourth quarter of this year.
  • Presented preclinical data at the AUA meeting announcing that D3263, a small molecule targeting TRPM8 (a transmembrane cation channel protein), reduced the size of the prostate in an animal model of benign prostatic hyperplasia (BPH) alone or in combination with finasteride.
  • Initiated a Phase 1 clinical trial of D3263 in patients with advanced cancer. The trial is an open-label, dose-escalation study evaluating the safety and pharmacokinetics of orally-administered D3263 targeting TRPM8 in patients with solid tumors that are refractory to standard therapies.

  • '/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
2. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
3. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
4. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
5. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
9. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
10. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
11. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... and its potential to revolutionize the world has ... multinational corporations and small start-ups. The early years ... research projects largely due to the high risks ... Government budgets earmarked for this evolving technology have ...
(Date:9/19/2014)... BioTech News Coverage: Progress made ... of studies and trials.  Companies in focus are: GenSpera ... LLY ), Gilead Sciences Inc. (NASDAQ: ... and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, ... for the treatment of cancer, announced that the United ...
(Date:9/19/2014)... The new , Healthcare and Life ... today on PharmaBoardroom.com for free download , ... the Spanish economy in 2009, and the austerity measures that ... pragmatic in times of trouble. "Despite the crisis, ... European market, and the general conditions to invest are favorable ...
(Date:9/18/2014)... A novel robotic system that can operate inside ... tested as part of a biomedical research partnership program ... aim of determining if the robot, in conjunction with ... more accurate, less costly, and less discomforting for the ... deliver prostate cancer therapies with greater precision. , Developed ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6
... 14, 2011 The global biotechnology industry delivered solid top- ... profitability for the second year in a row. ... scarce for the vast majority of firms in the sector, ... years of funding to support drug development. This has placed ...
... Arabic . DUBAI (14 June 2011)With increased trade ... prices, livestock experts from the Middle East and 12 African ... strategy that eliminates the need to impose devastating bans on ... the spread of Rift Valley fever. The strategy should expedite ...
... DNDN ) today announced that Mitchell H. Gold, M.D., ... Entrepreneur Of The Year ® 2011 Pacific ... Dr. Gold has served as CEO of Dendreon since 2003, ... Food and Drug Administration approval for PROVENGE® (sipuleucel-T) the first ...
Cached Biology Technology:Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 2Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 3Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 4Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 5Despite Renewed Growth in 2010, Biotech Industry Faces R&D Challenges 6East Africa and Middle East seek plan to keep animal diseases from disrupting livestock trade 2East Africa and Middle East seek plan to keep animal diseases from disrupting livestock trade 3Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner 2Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner 3Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner 4Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner 5
(Date:9/19/2014)... for the sake of fairness per se but in ... say Frans de Waal, PhD, and Sarah Brosnan, PhD, ... which is defined as a negative reaction to unequal ... , Their conclusion comes after the co-authors reviewed ... that it is the evolution of forestalling partner dissatisfaction ...
(Date:9/19/2014)... plants regulate their symbiotic relationship with soil bacteria ... the plant structure from leaves into the roots ... the roots. This collaborative study was conducted by ... the Graduate University for Advanced Studies (SOKENDAI), and ... Japan. , Legumes, an important plant family ...
(Date:9/18/2014)... located deep in the primitive brainstem has revealed how ... Harvard School of Medicine and the University at Buffalo ... the second "sleep node" identified in the mammalian brain ... to produce deep sleep. , Published online in August ... fully half of all of the brain,s sleep-promoting activity ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3For legume plants, a new route from shoot to root 2No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... in 2011 and 2012 made two unexpected discoveries that could ... and aid in the creation of a plan to protect ... along a transect that stretched from the open ocean, across ... bays and inlets around the Rock Islands of Palau, in ...
... research and the market. It helps good ideas for ... become fully-fledged commercial prospects, ready for use by business ... the aeronautic market, where it will be introduced as ... provide optimum corrosion protection, but are highly toxic. ...
... at the Nanoscience Center (NSC) of University of Jyvskyl in ... and their functions. The method will help to obtain new ... well as on the mechanisms of virus opening inside cells. ... antiviral drugs and vaccines. The study was published in the ...
Cached Biology News:Coral reefs in Palau surprisingly resistant to naturally acidified waters 2Coral reefs in Palau surprisingly resistant to naturally acidified waters 3Coral reefs in Palau surprisingly resistant to naturally acidified waters 4The Eco-Innovation initiative rewards ideas for innovative products that protect the environment 2Gold nanoparticles help to develop a new method for tracking viruses 2Gold nanoparticles help to develop a new method for tracking viruses 3
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
Biology Products: